Merck Healthcare Germany GmbH has alerted healthcare professionals to a quality defect concerning Digimerck 0.07 mg tablets. The sum of degradation products may slightly exceed the specification limit towards the end of the product's shelf life. Although distribution of this drug was halted in 2022, the communication emphasizes the need to monitor patients who may still be using remaining stock and to report any adverse effects.

Healthcare providers should be aware of this potential quality issue and proactively monitor patients using any residual Digimerck 0.07 mg tablets. Any observed side effects should be reported to the relevant authorities. While no immediate compliance actions are required due to the discontinuation of distribution, vigilance regarding patient safety and pharmacovigilance reporting remains critical.